• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Friday, August 14, 2020

    Time

    10:30 AM - 11:30 AM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    1 Contact Hour(s)

    Target Audience

    Pharmacist, Nurse

    Cost

    $30.00

    • Overview

      Direct oral anticoagulants (DOACs) are recognized by guidelines as first-line options for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalular atrial fibrillation.  The use of DOACs is wide-spread, and it is challenging to ensure patient safety as each agent has slightly different pharmacokinetic considerations with their use.  This program will address safety and efficacy with each agent, initial recommendations for dosing and adjustments based on renal considerations, drug interactions, and age and weight.  Common risk factors for bleeding will be identified as well as options in support of the management of bleeding, if it should occur, are proposed.


      Handouts

      Slide Document 20177L01_2pp.pdf
      Slide Document 20177L01_6pp.pdf





      Financial Support By

      PharmCon
    • Pharmacist

      Differentiate among direct acting anticoagulants available for the treatment of non-valvular atrial fibrillation and venous thromboembolism.
      Determine appropriate individualized treatment for patients based upon current literature and evidence based guidelines.
      Identify appropriate modifications of direct acting anticoagulants such as dose adjustments or optimization of therapy in patients at risk for diminished efficacy or bleeding.

      Nurse

      Differentiate among direct acting anticoagulants available for the treatment of non-valvular atrial fibrillation and venous thromboembolism.
      Determine appropriate individualized treatment for patients based upon current literature and evidence based guidelines.
      Identify appropriate modifications of direct acting anticoagulants such as dose adjustments or optimization of therapy in patients at risk for diminished efficacy or bleeding.
    • Repeat Presentation

      This presentation was last given on 8/14/2020 10:30 AM

      Future Airings

      Date Time
      Monday, November 2, 2020 10:30 AM View

    • Activity Type

      Knowledge

      CE Broker

      20-781426

      Universal Activity Number

      Pharmacist 0798-0000-20-177-L01-P

      Nurse 0798-0000-20-177-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Windows 8.1
    Windows 10
    Apple Mac OS X 10.13 or higher
    iOS 10+
    Android 4.3+


    SOFTWARE REQUIREMENTS
    Google Chrome
    Mozilla Firefox

    Log in locally; do not log in using a VPN, cloud server, remote desktop, etc.


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon. Through this notice, PharmCon. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.